Lungs News and Research

RSS

ACAAI to launch 15th annual Nationwide Asthma Screening Program

The nation's allergists help adults and children learn if they are at risk for asthma or exercise-induced bronchoconstriction as the American College of Allergy, Asthma and Immunology conducts its 15th annual Nationwide Asthma Screening Program.

31 Mar 2011

Study finds continued smoking after cancer diagnosis among patients, family caregivers

Nicotine is so addictive for many people that even a cancer diagnosis doesn't help them - or their family members and caregivers - throw the cigarettes away.

31 Mar 2011

Top-line results from Biomoda's CyPath pilot study against lung cancer

Cancer diagnostics company Biomoda, Inc. today announced top-line results of its pilot study for lung cancer which shows highly significant evidence of CyPath's ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.

31 Mar 2011

CCAC National Survey finds 82% of Canadians with cancer

The Colorectal Cancer Association of Canada today announced findings from the Weighing Quality of Life in Cancer National Survey showing that an alarming 82 per cent of Canadians have been touched closely by cancer and have had a close friend or family member battle cancer, or have done so themselves.

31 Mar 2011

Mucus may play a key role in penetration of hydrophobic substances into cells

Are our bodies vulnerable to some pollutants whose lack of solubility in water, or "hydrophobicity," has always been thought to protect us from them? New Tel Aviv University research has discovered that this is indeed the case.

31 Mar 2011

New study suggests link between migraine headaches and PFO in children

Roughly 15% of children suffer from migraines, and approximately one-third of these affected children have migraines with aura, a collection of symptoms that can include weakness, blind spots, and even hallucinations.

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Study examines plant-soil relationship and uptake of contaminants in ryegrass

The environmental concern is great when considering the role of toxic contaminants in the plant-soil relationship. Understanding plant's absorption and accumulation of these contaminants from the soil would be incredibly beneficial.

30 Mar 2011

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Eya1 protein phosphatase is a crucial regulator of the development of embryonic lung epithelial stem cells.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

New lung cancer drug starts human trials

A new drug for lung cancer is being tried by researchers at Oxford. The treatment, which halts the growth of cancer cells, is being trialed on those patients who have stopped responding to chemotherapy. The trial is one of the first to go ahead at the Oxford Cancer Research Centre.

29 Mar 2011

Natural disasters can produce major lung problems

A comprehensive new review published in the journal Respirology indicates that lung problems are major causes of morbidity and mortality following natural disasters.

29 Mar 2011

Smoking cessation after liver transplantation reduces incidence of malignancy

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies (SRM) than patients who keep smoking. In fact, SRMs were identified in 13.5% of deceased patients and smoking was associated with a higher risk of malignancy in this study. Full findings are published in the April issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2011

Study: Donor's DNA level in heart transplant recipient's blood can reveal organ rejection

Heart transplant recipients and their physicians are likely more concerned with the function of the donated organ than with the donor's DNA sequences that tag along in the new, healthy tissue.

29 Mar 2011

International Phase II trial to study LY2181308 efficacy in patients with lung cancer

Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy treatment. The trial will take place at the Oxford Radcliffe Hospitals NHS Trust.

29 Mar 2011

Altitude Research Center receives Department of Defense grant to prevent AMS in soldiers

As the American military rushes to confront adversaries in some of the world's highest mountain ranges, the Department of Defense is giving $4 million to the Altitude Research Center at the University of Colorado School of Medicine to develop revolutionary ways to combat high altitude sickness in soldiers, sailors and marines.

29 Mar 2011

FDA approves Medtronic's Protecta implantable defibrillators

Medtronic, Inc. today announced U.S. Food and Drug Administration approval of the Protecta portfolio of implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators.

29 Mar 2011